Momentum Bioscience Ltd recently hosted a visit by David Cameron, MP for Witney and Prime Minister at its facility in Long Hanborough, Oxfordshire. Mr Cameron unveiled a commemorative plaque, toured the new research and development laboratories and discussed the company’s innovative products and future plans.
Professor Woodford (PHE), Mr Cameron and William Mullen (CEO)
Joining the visit was Momentum’s research collaborator, Professor Neil Woodford, Head of the AntimicrobialResistance and Healthcare Associated Infections (AMRHAI) reference unit at Public Health England and advisor to the Prime Minister’s O’Neill review. Professor Woodford discussed with Mr Cameron how new diagnostic tools help in reducing antibiotic use and resistance.
Mr Cameron in discussion with Professor Woodford
Mr Cameron concluded his visit by addressing the directors, management and employees of Momentum. He said ‘Momentum Bioscience is a good example of innovation and research in West Oxfordshire and I am pleased to see how the company has benefited from government backed investment funding and grant support. He added ‘The fight against antibiotic resistance and the overuse of antibiotics is a high priority for the government and Momentum’s innovative technology and diagnostic products can make a valuable contribution in this area’.
Dr William Mullen, CEO said ’We are very pleased that Mr Cameron was able to visit Momentum and see our progress as a growing company. His interest in the issues of antibiotic use and resistance is clear and we value his support as our local MP’.
Notes to Editors
Momentum was founded to create rapid tests for critically-important clinical specimens within the hospital microbiology laboratory. The Company is backed by its founders, business angels and venture capital and is led by a management team with extensive experience in the development and commercialisation of novel diagnostic products. Momentum is headquartered near Cardiff with an R&D facility near Oxford. Its first product, Cognitor® Minus, allows rapid reporting of negative blood specimens from patients suspected of sepsis, allowing early cessation of unnecessary antibiotics. Cognitor® Minus achieved a CE mark earlier this year.
James Collier, Commercial Director: +44 (0)29 2167 7910